ATE446767T1 - Gm-csf zur behandlung von morbus crohn - Google Patents

Gm-csf zur behandlung von morbus crohn

Info

Publication number
ATE446767T1
ATE446767T1 AT00913421T AT00913421T ATE446767T1 AT E446767 T1 ATE446767 T1 AT E446767T1 AT 00913421 T AT00913421 T AT 00913421T AT 00913421 T AT00913421 T AT 00913421T AT E446767 T1 ATE446767 T1 AT E446767T1
Authority
AT
Austria
Prior art keywords
csf
disease
crohn
treatment
factors
Prior art date
Application number
AT00913421T
Other languages
English (en)
Inventor
Brian Dieckgraefe
Joshua Korzenick
Original Assignee
Univ Washington
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Washington filed Critical Univ Washington
Application granted granted Critical
Publication of ATE446767T1 publication Critical patent/ATE446767T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Zoology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Studio Devices (AREA)
  • Silicon Compounds (AREA)
  • Treatment Of Sludge (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT00913421T 1999-02-12 2000-02-11 Gm-csf zur behandlung von morbus crohn ATE446767T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11984299P 1999-02-12 1999-02-12
PCT/US2000/003407 WO2000047195A1 (en) 1999-02-12 2000-02-11 Stimulating neutrophil function to treat inflammatory bowel disease

Publications (1)

Publication Number Publication Date
ATE446767T1 true ATE446767T1 (de) 2009-11-15

Family

ID=22386711

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00913421T ATE446767T1 (de) 1999-02-12 2000-02-11 Gm-csf zur behandlung von morbus crohn

Country Status (7)

Country Link
EP (1) EP1150666B1 (de)
JP (2) JP2002536404A (de)
AT (1) ATE446767T1 (de)
AU (1) AU764681C (de)
CA (1) CA2367575A1 (de)
DE (1) DE60043216D1 (de)
WO (1) WO2000047195A1 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6500418B1 (en) * 1999-02-12 2002-12-31 The Washington University Stimulating neutrophil function to treat inflammatory bowel disease
CN1816345A (zh) * 2003-05-16 2006-08-09 协和发酵工业株式会社 伴有组织破坏的疾病的预防剂和/或治疗剂
WO2005084702A1 (ja) * 2004-03-02 2005-09-15 Hokkaido Technology Licensing Office Co., Ltd. 臓器線維症予防・治療剤
WO2007134907A2 (en) * 2006-05-18 2007-11-29 Bayer Schering Pharma Aktiengesellschaft Gm-csf gene therapy for treatment of crohn's disease using an improved regulated expression system

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU594014B2 (en) * 1984-03-21 1990-03-01 Research Corporation Technologies, Inc. Recombinant DNA molecules
DE3584089D1 (de) * 1984-07-06 1991-10-17 Sandoz Ag Herstellung und reinigung von lymphokinen.
ZA856108B (en) * 1984-10-29 1986-10-29 Immunex Corp Cloning of human granulocyte-macrophage colony simulating factor gene
DE3853590T2 (de) * 1987-06-25 1996-01-04 Immunex Corp Rinder granulocyt-makrophagenkolonie stimulierender faktor.
US4961926A (en) * 1987-11-19 1990-10-09 Sloan-Kettering Institute For Cancer Research Methods for prevention and treatment of mucositis with granulocyte colony stimulating factor
US5654186A (en) * 1993-02-26 1997-08-05 The Picower Institute For Medical Research Blood-borne mesenchymal cells
US5767156A (en) * 1993-10-06 1998-06-16 Peptide Technology Limited Polyunsaturated fatty acids and uses thereof
US5733915A (en) * 1995-03-30 1998-03-31 Glaxo Wellcome Inc. Use of azathioprine to treat crohn's disease
US6037324A (en) * 1996-01-04 2000-03-14 Leukosite, Inc. Inhibitors of MAdCAM-1-mediated interactions and methods of use therefor
US5846983A (en) * 1996-02-09 1998-12-08 Mayo Foundation For Medical Education And Research Colonic delivery of nicotine to treat inflammatory bowel disease
NZ500696A (en) * 1997-04-01 2002-05-31 Borody Thomas J Methods and compositions for treating inflammatory bowel disease comprising mycobacterial agents, including macrolides
DE19835080A1 (de) * 1998-07-27 2000-02-03 Doecke Wolf Dietrich Mittel zur Behandlung des Krankheitsbildes Morbus Crohn

Also Published As

Publication number Publication date
JP2005225890A (ja) 2005-08-25
AU764681C (en) 2005-07-07
EP1150666B1 (de) 2009-10-28
AU764681B2 (en) 2003-08-28
EP1150666A1 (de) 2001-11-07
EP1150666A4 (de) 2003-07-02
CA2367575A1 (en) 2000-08-17
WO2000047195A1 (en) 2000-08-17
DE60043216D1 (de) 2009-12-10
AU3487100A (en) 2000-08-29
JP2002536404A (ja) 2002-10-29

Similar Documents

Publication Publication Date Title
MY155218A (en) Small molecules useful in the treatment of inflammatory disease
IL267381A (en) A pharmaceutical preparation containing dextromethorphan and quinidine for the treatment of nervous disorders
LTC1131065I2 (lt) Dialkilfumaratai, skirti autoimuninėms ligoms gydyti
DE69030880D1 (de) Zusammensetzung zur Stimulierung des Immunsystems
EA200601575A1 (ru) Казеиновые пептиды и их терапевтическое применение
ATE87214T1 (de) Verwendung katabolischer enzyme zur herstellung eines medikaments zum bekaempfen der erworbenen immunschwaeche (aids) und deren vorstadien (las, arc).
NO175042C (de)
NO20014415D0 (no) Medisinske preparater til behandling av <alfa>-galaktosidase- A-defisiens
SG146666A1 (en) Methods of using regenerative cells in the treatment of peripheral vascular disease and related disorders
ATE232396T1 (de) Oxydiertes thymosin beta 4
SE9301290D0 (sv) Anvaendning av en somatostatinanalog
DE60130775D1 (de) Stimulierung der neutrophilfunktion zur behandlung von entzündlichen darmerkrankungen
ATE446767T1 (de) Gm-csf zur behandlung von morbus crohn
ATE81467T1 (de) Immunosuppression bei der auf immunotoxin basierten behandlung von menschen.
MXPA00010254A (es) Tratamiento de disfuncion sexual en ciertos grupos de pacientes.
ATE81462T1 (de) Glykosaminoglykan zur behandlung von diabetischer mikroangiopathie.
DE69929616D1 (de) Oxyhuminsäure und ihre verwendung zur behandlung von verschiedenenen störungen
HUP0003845A2 (hu) Antimikrobiális 8a-azalidok alkalmazása
ATE128964T1 (de) Anwendung von beta-alethin in zellkultur und therapie.
HUP9903679A2 (hu) Olanzapin alkalmazása bipoláris zavar kezelésére szolgáló gyógyszerkészítmények előállítására
UA34283A (uk) Спосіб діагностики порушень імунологічного статусу у людини та тварин
UA69988A (en) Method for treating complicated choledocholithiasis

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties